Roquefort Therapeutics plc (LON: ROQ)

Market Cap	5.10M
Revenue (ttm)	n/a
Net Income (ttm)	-1.54M
Shares Out	129.15M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,551,730
Open	4.100
Previous Close	3.950
Day's Range	3.813 - 4.380
52-Week Range	3.300 - 9.500
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy, toxicology studies, and orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in vivo effica...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: ROQ